PTH-124 The use of tacrolimus in patients with ulcerative colitis resistant to standard medical therapy. (June 2019)

• Record Type: Journal Article
• Authors: Shafi, Taimur; Bedir, Abdulla; Medcalf, Lucy; Chung-Faye, Guy; Hope, Benjamin; Dubois, Patrick; Haye, Bu; Vadamalayan, Babu; Kent, Alexandra J
• Is Part Of: Gut. Volume 68(2019)Supplement 2
• Page Start: A96
• Page End: A97
• Publication Date: 2019-06
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2019-BSGAbstracts.183
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: BSG guidelines support the use of tacrolimus in selected adult or paediatric patients with ulcerative colitis (UC) resistant to standard therapy. Despite these guidelines, in our experience tacrolimus is used infrequently. We present the outcomes of 21 UC patients commenced on tacrolimus at Kings College Hospital NHS Trust. Methods: The King's College Hospital electronic patient records database was searched, including all records from January 2011 to October 2018. The search was performed using the terms, 'ulcerative colitis' and 'tacrolimus.' All records were interrogated to collect retrospective data. Results: Our search yielded a total of 275 patients. 191 were excluded as they were on tacrolimus for an indication other than UC. A further 59 were discounted as tacrolimus was never commenced. 4 were removed where tacrolimus topical ointment was used. 21 UC patients (16 adult, 5 paediatric) treated with tacrolimus were identified. Mean age was 29 years (range 9 – 62), M:F 13:8, 13 Caucasian, 4 Afro-Caribbean, 2 Asian and 2 unspecified. 81% had pancolitis, 3 left-sided disease and 1 proctitis. All 21 patients had previously been treated with 5-aminosalicylates (5-ASAs) and steroids. In addition to the 5-ASAs and steroids: 12 patients were treated with both azathioprine (Aza) and a biologic; 4 patients only received Aza; 2 only a biologic; 1 only mycophenolate mofetil; 1 only mercaptopurine and 1 had no information. Mean duration on tacrolimus was 11 months (median 5; range, 0 – 66). 2 patients were primary non-responders and 9 terminated therapy due to adverse drug effects such as tremor, nausea and renal toxicity. 10 (48%) patients had a sustained clinical response remaining on tacrolimus for a mean of 21 months. 1 remains on tacrolimus currently, but 9 patients have had disease recurrence, with 6 patients requiring a colectomy, at an average of 16 months after starting tacrolimus. Faecal calprotectin (FCP) was used as an objective measure of disease activity. In patients on tacrolimus for a sustained period (n=10), there was a significant reduction in FCP. Mean FCP levels pre- and during treatment were 2574 and 381 respectively (mean difference 2197, CI 3237 to -1157, p0.001) [figure 1]. Conclusion: If tolerated, tacrolimus can be an effective treatment option for patients with ulcerative colitis. This response was maintained for an average of 21 months, with a significant drop in faecal calprotectin levels.